An analysis of AML patients found a higher risk of relapse in those treated with G-CSF who had increased quantities of G-CSF receptor (G-CSFR) isoform IV in blasts at diagnosis [57]. This evidence concerns the gene CSF3R and acute myeloid leukemia.